Anti-arrhythmic drugs

Phase 3Small molecule

Anti-arrhythmic drugs is one of 40 small molecule programs targeting Ventricular Tachycardia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ventricular TachycardiaActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Ventricular TachycardiaPreclinical

Active, not recruiting

Paroxysmal Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Paroxysmal Atrial Fibrillation

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

1 2

Tambocor

AAlvogen Korea

Approved

4 3

Calan

VVal Adams

Approved

1 4

Benicar

Novartis

Phase 3

1 5

Avapro

Sanofi

Phase 3

1 6

Pradaxa

Boehringer Ingelheim

Phase 3

1 7

Cordarone

WWyeth-Lederle Vaccines

Phase 3

1 8

Vernakalant

AAdvanz Pharma

Approved

1 9

Antiarrhythmic Drugs

NNational Institute of Cardiology, Warsaw, Poland

Approved

1 10

Multaq

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ventricular Tachycardia1 trial

Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

Active, not recruiting·WWestern Sydney Local Health District·N/A·NCT05524077·162 enrolled

Paroxysmal atrial fibrillation1 trial

Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation

Terminated·CC. R. Bard·Phase 3·NCT00741611·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-arrhythmic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-arrhythmic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-arrhythmic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — C. R. Bard company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CC. R. Bard

Anti-arrhythmic drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ventricular Tachycardia1 trial

Paroxysmal atrial fibrillation1 trial

References

Drug Info

Quick Facts

Related News